Faculty profile

Kevin Song

Back to faculty

ProfessorUniversity of British Columbia

Signals and details

Research

Read how they describe their research on their University of British Columbia profile.

Latest papers

Real-world outcomes of patients with multiple myeloma who reach third-line therapy: a Canadian report
Blood Neoplasia · 2026
Real-World Outcomes in Myeloma Patients With t (11;14): A Matched Comparison Using the Canadian Myeloma Research Group National Clinical Database
Clinical Lymphoma, Myeloma and Leukemia · 2026
Salvage Autologous Stem Cell Transplantation Outcomes and The Use of Maintenance in Relapsed Multiple Myeloma: Real world evidence from the Canadian Myeloma Research Group Database
Clinical Lymphoma, Myeloma and Leukemia · 2026

All 60 publications

Latest funding

A Phase I trial of single domain antibody-based CD22 chimeric antigen receptor (CAR)-T cells for the treatment of relapsed/refractory CD22+ B-cell acute lymphoblastic leukemia
CIHR · 2022 · Co-investigator
$3,051,528
A Phase I trial of single domain antibody-based CD22 chimeric antigen receptor (CAR)-T cells for the treatment of relapsed/refractory CD22+ B-cell acute lymphoblastic leukemia
CIHR · 2022 · Co-investigator
$762,882

All 2 grants and awards

60 publications.

Real-world outcomes of patients with multiple myeloma who reach third-line therapy: a Canadian report

Louzada ML, Reece D, Venner CP, White D, Su J, Chu MP, Zepeda VHJ, Mccurdy A, Song K, Mian H

Blood Neoplasia2026

DOI: 10.1016/j.bneo.2026.100215

Real-World Outcomes in Myeloma Patients With t (11;14): A Matched Comparison Using the Canadian Myeloma Research Group National Clinical Database

Varghese J, Venner CP, Louzada M, Reece D, White D, Sharma S, Su J, Chu MP, Jimenez-Zepeda VH, McCurdy A

Clinical Lymphoma, Myeloma and Leukemia2026

DOI: 10.1016/j.clml.2025.10.019

Salvage Autologous Stem Cell Transplantation Outcomes and The Use of Maintenance in Relapsed Multiple Myeloma: Real world evidence from the Canadian Myeloma Research Group Database

Kaedbey R, Venner CP, Reece D, Hay K, Gul E, Su J, McCurdy A, Chu MP, Jimenez-Zepeda VH, Song K

Clinical Lymphoma, Myeloma and Leukemia2026

DOI: 10.1016/j.clml.2025.10.026

Daratumumab-bortezomib-cyclophosphamide-dexamethasone for newly diagnosed amyloidosis: ANDROMEDA final survival analysis.

Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Sanchorawala V, Mollee P, Lu J, Schönland S, Gatt ME, Suzuki K, Kim K, Cibeira MT, Bhutani M, Beksac M, Libby E, Valent J, Hungria V, Rosenzweig M, Bumma N, Huart A, Dimopoulos MA, Bhutani D, Waxman AJ, Goodman SA, Zonder JA, Lam S, Song K, Hansen T, Manier S, Roeloffzen W, Jamroziak K, Kwok F, Shimazaki C, Kim JS, Crusoe E, Tran N, Wang J, Chen Y, Vasey SY, Schecter JM, Vermeulen J, Comenzo RL, Merlini G, ANDROMEDA Trial Investigators

Blood2026

DOI: 10.1182/blood.2025032099 PMID: 42118698

Determinants of clinical trial participation in multiple myeloma: A population-based cohort study from British Columbia.

Li H, Wong T, Rouhi A, Abou-Mourad Y, Cherniawsky H, Chung S, Forrest D, Lad D, Nantel S, Narayanan S, Nevill T, Nguyen A, Panahi A, Bakharzi M, Parkin S, Piechnik C, Rodrigo J, Roy C, Sanford D, Stubbins RJ, Toze C, Varghese J, White J, Wong E, Sutherland H, Song K, Venner CP, Kuchenbauer F

Leukemia research2026

DOI: 10.1016/j.leukres.2026.108254 PMID: 42224877

Heterogeneous survival outcomes in molecularly defined acute myeloid leukemia with myelodysplasia-related changes.

Chornenki N, Fadul A, Supan A, Abou Mourad Y, Cherniawsky H, Chung S, Forrest D, Lad D, Karsan A, Kuchenbauer F, McGinnis E, Nantel S, Narayanan S, Nevill T, Rodrigo J, Roy C, Song K, Toze C, White J, Sanford D, Stubbins RJ

Blood neoplasia2026

DOI: 10.1016/j.bneo.2026.100198 PMID: 41798677

Treatment Patterns and Outcomes of Multiple Myeloma Patients Undergoing Second-Line Therapy: A Canadian Myeloma Research Group (CMRG) Analysis

McCurdy A, Gul E, Reece D, Chu MP, Jimenez-Zepeda VH, Louzada M, Song K, Mian H, Sebag M, White D

Clinical Lymphoma, Myeloma and Leukemia20252 citations

DOI: 10.1016/j.clml.2025.02.011

Real-World Impact of Routine Addition of Antithymocyte Globulin to Standard GVHD Prophylaxis in Myeloablative Unrelated Donor Transplants: Important Gains in Graft-versus-Host Disease Prevention though No Difference in Overall Survival.

Bai N, Limvorapitak W, Henderson R, Abou Mourad Y, Chung S, Forrest D, Hay K, Kuchenbauer F, Nantel S, Narayanan S, Nevill T, Power M, Rodrigo J, Roy C, Sanford D, Song K, Stubbins R, Sutherland H, Toze C, White J

Acta haematologica2025

DOI: 10.1159/000541071 PMID: 39197435

Tandem Autologous Stem Cell Transplantation Does Not Benefit High-Risk Myeloma Patients in the Maintenance Era: Real-World Results from The Canadian Myeloma Research Group Database

Venner CP, Duggan P, Song K, Reece D, Sharma S, Su J, Jimenez-Zepeda VH, McCurdy A, Louzada M, Mian H

Transplantation and Cellular Therapy20249 citations

DOI: 10.1016/j.jtct.2024.06.030

Long‐term follow‐up of outcomes including progression‐free survival 2 in patients with transplant‐ineligible multiple myeloma in the real‐world practice: A multi‐institutional report from the Canadian Myeloma Research Group (CMRG) database

Kaedbey R, Reece D, Venner CP, McCurdy A, Su J, Chu M, Louzada M, Jimenez‐Zepeda VH, Mian H, Song K

eJHaem20245 citations

DOI: 10.1002/jha2.894

Profile data last refreshed on September 27, 2026 from the university directory, publication records and CIHR, NSERC and SSHRC funding.

Something wrong or missing on this profile? Suggest a correction

Kevin Song

Research

Latest papers

Latest funding

Real-world outcomes of patients with multiple myeloma who reach third-line therapy: a Canadian report

Real-World Outcomes in Myeloma Patients With t (11;14): A Matched Comparison Using the Canadian Myeloma Research Group National Clinical Database

Salvage Autologous Stem Cell Transplantation Outcomes and The Use of Maintenance in Relapsed Multiple Myeloma: Real world evidence from the Canadian Myeloma Research Group Database

Daratumumab-bortezomib-cyclophosphamide-dexamethasone for newly diagnosed amyloidosis: ANDROMEDA final survival analysis.

Determinants of clinical trial participation in multiple myeloma: A population-based cohort study from British Columbia.

Heterogeneous survival outcomes in molecularly defined acute myeloid leukemia with myelodysplasia-related changes.

Treatment Patterns and Outcomes of Multiple Myeloma Patients Undergoing Second-Line Therapy: A Canadian Myeloma Research Group (CMRG) Analysis

Real-World Impact of Routine Addition of Antithymocyte Globulin to Standard GVHD Prophylaxis in Myeloablative Unrelated Donor Transplants: Important Gains in Graft-versus-Host Disease Prevention though No Difference in Overall Survival.

Tandem Autologous Stem Cell Transplantation Does Not Benefit High-Risk Myeloma Patients in the Maintenance Era: Real-World Results from The Canadian Myeloma Research Group Database

Long‐term follow‐up of outcomes including progression‐free survival 2 in patients with transplant‐ineligible multiple myeloma in the real‐world practice: A multi‐institutional report from the Canadian Myeloma Research Group (CMRG) database

A Phase I trial of single domain antibody-based CD22 chimeric antigen receptor (CAR)-T cells for the treatment of relapsed/refractory CD22+ B-cell acute lymphoblastic leukemia

A Phase I trial of single domain antibody-based CD22 chimeric antigen receptor (CAR)-T cells for the treatment of relapsed/refractory CD22+ B-cell acute lymphoblastic leukemia

Frequent collaborators

Donna Reece

Michael Sebag

Arleigh McCurdy

Martha Louzada

Hira Mian

Alissa Visram

Deepesh Lad

Aly Karsan

Nizar Bahlis

Andrew Roth

Kednapa Thavorn

Christopher Venner

Tony Reiman

Suzanne Trudel

John Kuruvilla

Kevin Hay

Natasha Kekre

Terry Hawrysh

Jennifer Quizi

Parveen Bhatti

Maryam Darvishian